1. Stratigos, AJ, Garbe, C, Dessinioti, C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention. Eur J Cancer 2020; 128: 60–82.
Google Scholar | Crossref | Medline2. Alam, M, Armstrong, A, Baum, C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2018; 78: 560–578.
Google Scholar | Crossref | Medline3. Amaral, T, Osewold, M, Presser, D, et al. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol 2019; 33(Suppl. 8): 44–51.
Google Scholar | Crossref | Medline4. Nelson, TG, Ashton, RE. Low incidence of metastasis and recurrence from cutaneous squamous cell carcinoma found in a UK population: do we need to adjust our thinking on this rare but potentially fatal event? J Surg Oncol 2017; 116: 783–788.
Google Scholar | Crossref | Medline5. Brantsch, KD, Meisner, C, Schonfisch, B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713–720.
Google Scholar | Crossref | Medline | ISI6. Schmults, CD, Karia, PS, Carter, JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149: 541–547.
Google Scholar | Crossref | Medline | ISI7. Peris, K, Alaibac, M, Argenziano, G, et al. Cutaneous squamous cell carcinoma. Italian guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. G Ital Dermatol Venereol 2018; 153: 747–762.
Google Scholar | Crossref | Medline8. Brancaccio, G, Fargnoli, MC, Briatico, G, et al. Risk factors and diagnosis of advanced cutaneous squamous cell carcinoma. Dermatol Pract Concept 2021; 11: e2021166S.
Google Scholar | Crossref9. Venables, ZC, Autier, P, Nijsten, T, et al. Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England. JAMA Dermatol 2019; 155: 298–306.
Google Scholar | Crossref | Medline10. Amin, MB, Edge, S, Greene, F, et al. AJCC cancer staging manual. 8th ed. Cham: Springer, 2017.
Google Scholar | Crossref11. Brierley, JD, Gospodarowicz, MK, Wittekind, C. TNM classification of malignant tumours. 8th ed. Hoboken, NJ: Wiley-Blackwell, 2017.
Google Scholar12. Jambusaria-Pahlajani, A, Kanetsky, PA, Karia, PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013; 149: 402–410.
Google Scholar | Crossref | Medline | ISI13. Bottomley, MJ, Thomson, J, Harwood, C, et al. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci 2019; 20: 2009.
Google Scholar | Crossref14. Migden, MR, Rischin, D, Schmults, CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379: 341–351.
Google Scholar | Crossref | Medline15. Mellman, I, Coukos, G, Dranoff, G. Cancer immunotherapy comes of age. Nature 2011; 480: 480–489.
Google Scholar | Crossref | Medline | ISI16. Topalian, SL, Drake, CG, Pardoll, DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450–461.
Google Scholar | Crossref | Medline | ISI17. Stevenson, ML, Wang, CQ, Abikhair, M, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol 2017; 153: 299–303.
Google Scholar | Crossref | Medline18. European Medicines Agency . Libtayo (cemiplimab): EPAR – product information, https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo#product-information-section (2019, accessed 27 July 2020).
Google Scholar19. US Food and Drug Administration . Libtayo (cemiplimab-rwlc) injection, for intravenous use: highlights of prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf (2018, accessed 27 July 2020).
Google Scholar20. Stratigos, AJ, Garbe, C, Dessinioti, C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Eur J Cancer 2020; 128: 83–102.
Google Scholar | Crossref | Medline21. National Institute of Health and Care Excellence . Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma. Technology appraisal guidance [TA592], https://www.nice.org.uk/guidance/TA592 (2019, accessed 11 August 2020).
Google Scholar22. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): squamous cell skin cancer, version 2.2021, https://www.nccn.org (2021, accessed 17 February 2021).
Google Scholar23. Soura, E, Gagari, E, Stratigos, A. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? Curr Opin Oncol 2019; 31: 461–468.
Google Scholar | Crossref | Medline24. Skin tumours . In: Brierley, JD, Gospodarowicz, MK, Eittekind, C (eds) TNM classification of malignant tumours. 8th ed. Hoboken, NJ: John Wiley & Sons Inc., 2017, pp. 131–149.
Google Scholar25. Migden, MR, Khushalani, NI, Chang, ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020; 21: 294–305.
Google Scholar | Crossref | Medline26. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): squamous cell skin cancer NCCN evidence blocks, version 2.2020, https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf (2020, accessed 21 October 2020).
Google Scholar27. Jarkowski, A, Hare, R, Loud, P, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature. Am J Clin Oncol 2016; 39: 545–548.
Google Scholar | Crossref | Medline28. Montaudié, H, Viotti, J, Combemale, P, et al. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. Oncotarget 2020; 11: 378–385.
Google Scholar | Crossref | Medline29. Maubec, E, Petrow, P, Scheer-Senyarich, I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419–3426.
Google Scholar | Crossref | Medline30. Dereure, O, Missan, H, Girard, C, et al. Efficacy and tolerance of cetuximab alone or combine with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients. Dermatology 2016; 232: 721–730.
Google Scholar | Crossref | Medline31. Regeneron Pharmaceuticals . A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), as single therapy and in combination with other anti-cancer therapies in patients with advanced malignancies (ClinicalTrials.gov record: NCT02383212), https://clinicaltrials.gov/ct2/show/NCT02383212 (2015, accessed 27 July 2020).
Google Scholar32. Regeneron Pharmaceuticals . A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with advanced cutaneous squamous cell carcinoma (ClinicalTrial.gov record: NCT02760498), https://clinicaltrials.gov/ct2/show/NCT02760498 (2016, accessed 27 July 2020).
Google Scholar33. Rischin, D, Khushalani, NI, Schmults, CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021; 9: e002757.
Google Scholar | Crossref | Medline34. Büttner, R, Longshore, JW, López-Ríos, F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 2019; 4: e000442.
Google Scholar | Crossref | Medline35. Goodman, AM, Kato, S, Bazhenova, L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 2017; 16: 2598–2608.
Google Scholar | Crossref | Medline | ISI36. Samstein, RM, Lee, CH, Shoushtari, AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51: 202–206.
Google Scholar | Crossref | Medline37. Rischin, D, Migden, MR, Lim, AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 2020; 8: e000775.
Google Scholar | Crossref | Medline38. Rischin, D, Khushalani, NI, Schmults, CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up. J Clin Oncol 2020; 38: 10018.
Google Scholar | Crossref39. Thompson, AK, Kelley, BF, Prokop, LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 2016; 152: 419–428.
Google Scholar | Crossref | Medline40. Hillen, U, Leiter, U, Haase, S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns – results of a non-interventional study of the DeCOG. Eur J Cancer 2018; 96: 34–43.
Google Scholar | Crossref | Medline41. Lee, A, Duggan, S, Deeks, ED. Cemiplimab: a review in advanced cutaneous squamous cell carcinoma. Drugs 2020; 80: 813–819.
Google Scholar | Crossref | Medline42. Gross, N, Ferrarotto, R, Nagarajan, P, et al. LBA74 – phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Ann Oncol 2019; 30: v910.
Google Scholar | Crossref | Medline